GlobeNewswire·May 7, 2026, 4:05 PM ET

Aligos Therapeutics Reports Recent Business Progress and First Quarter 2026 Financial Results

ALGS

Aligos Therapeutics reported first-quarter 2026 financial results & recent business progress on May 7, 2026.
Pevifoscorvir sodium received Fast Track Designation from the FDA for chronic HBV infection.
The Phase 2 B-SUPREME study for pevifoscorvir sodium continued after a first interim analysis showed no futility & the Drug Safety Monitoring Board recommended increasing the HBeAg- cohort sample size from 74 to 100 participants.
Study drugs were well-tolerated with no clinically concerning abnormalities or viral breakthrough observed to date.
Aligos entered an exclusive license deal with Amoytop for pevifoscorvir sodium in Greater China, securing a $25 million upfront payment & potential up to $420 million in milestones.
ALG-170675, a best-in-class ASO for chronic HBV infection, began IND-enabling studies with Amoytop funding development costs in China.
Cash, cash equivalents, & investments totaled $54.9 million as of March 31, 2026, providing sufficient funding through the fourth quarter of 2026.
The company reported a net loss of $23.0 million for the quarter, compared to a net income of $43.1 million in the same period in 2025.
Research and development expenses increased to $23.4 million from $14.5 million in the prior year period due to higher third-party costs for the pevifoscorvir sodium Phase 2 trial.
General and administrative expenses rose to $6.4 million from $5.1 million, primarily driven by increases in stock-based compensation despite lower legal expenses.
A $3.4 million income from the change in fair value of 2023 common warrants was recorded, compared to $61.5 million in the prior year period.
Topline data for the HBeAg- & HBeAg+ cohorts of the B-SUPREME study is expected in 2027.